April 29, 2020 / 12:54 PM / a month ago

BRIEF-Gilead Sciences Says Aware Of Positive Data Emerging From NIAID's Study Of Investigational Antiviral Remdesivir

April 29 (Reuters) - Gilead Sciences Inc:

* GILEAD SCIENCES STATEMENT ON POSITIVE DATA EMERGING FROM NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES’ STUDY OF INVESTIGATIONAL ANTIVIRAL REMDESIVIR FOR COVID-19

* GILEAD SCIENCES INC - UNDERSTAND THAT TRIAL HAS MET ITS PRIMARY ENDPOINT AND THAT NIAID WILL PROVIDE DETAILED INFORMATION AT AN UPCOMING BRIEFING

* GILEAD SCIENCES INC - AWARE OF POSITIVE DATA EMERGING FROM NIAID’S STUDY OF INVESTIGATIONAL ANTIVIRAL REMDESIVIR FOR TREATMENT OF COVID-19

* GILEAD - REMDESIVIR IS NOT YET LICENSED/APPROVED ANYWHERE GLOBALLY AND HAS NOT YET BEEN DEMONSTRATED TO BE SAFE OR EFFECTIVE FOR TREATMENT OF COVID-19

* GILEAD SCIENCES - WILL SHARE ADDITIONAL REMDESIVIR DATA FROM OPEN-LABEL PHASE 3 SIMPLE TRIAL IN PATIENTS WITH SEVERE COVID-19 DISEASE SHORTLY

* GILEAD SCIENCES - SEES DATA AT END OF MAY FROM 2ND SIMPLE STUDY EVALUATING 5- AND 10-DAY DOSING DURATIONS OF REMDESIVIR IN PATIENTS WITH MODERATE COVID-19 DISEASE

* GILEAD - PHASE 3 SIMPLE TRIAL WILL PROVIDE INFORMATION ON IF SHORTER, 5-DAY DURATION OF THERAPY MAY HAVE SIMILAR EFFICACY AND SAFETY AS 10-DAY TREATMENT COURSE IN NIAID TRIAL Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below